ArticleRSC medicinal chemistry2026
Bioactivity studies of organometallic Cp*Rh(iii) and Au(i) NHC complexes bioconjugated to integrin binding peptides.
Article in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrins are pivotal targets in cancer therapy development due to their overexpression in many tumor cells and neovascular tissue. Arginine-glycine-aspartic acid (RGD) sequence-containing peptides are established ligands for targeting integrins; approximately half of all known integrins recognize this sequence, enabling selective delivery of drugs and imaging agents to tumors and their vasculature. Despite the widespread application of cyclic RGD (cRGD) peptides in oncological research, the number of reported RGD conjugates featuring organometallic payloads remains limited. In this work, we present new Au(i) and Rh(iii) organometallic cRGD conjugates and study their bioactivity by a combination of experimental and theoretical methods. The three organometallic bioconjugates, labelled
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.